Big Pharma Merck is scheduled to report its second-quarter earnings results on July 28. Here are three questions investors are expecting to have answered on that date.
Big Pharma Pfizer is on deck with its Q2 earnings results. See what questions and concerns Wall Street and investors expect Pfizer to address.
It's true that the broad-based S&P 500 has more than tripled since March 2009, but there are still plenty of enticing value stocks worth considering if you're willing to do some digging.
Big Pharma companies are truly in a class of their own. Here are seven facts about the industry you may not be aware of.
Johnson & Johnson kicks off earnings season for the pharmaceutical sector and answers some very important questions and concerns in the process.
ExxonMobil has looked bleak for a while, and shares have plunged. Which begs the question, has the price fallen low enough to warrant plunging in for some deep value, or is Exxon more of a value trap?
Even though the term "bubble" is being tossed around with regard to biotech stocks, there are still three undervalued stocks in the sector worth buying.
The market might be in rally mode, but these three value stocks still stand out as being potentially bargain-priced.
These three value stocks may have been clobbered in recent months, but they all may be poised for substantial rebounds.
These three stocks might have been pummeled recently, but they could rebound in a big way.